Drugs / Mytomicin C
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 4 | NCT05250648 Comparator | Mar 2022 → Oct 2029 expected | colon carcinoma, peritoneal carcinomatosis | Hospital Universitario de Fuenlabrada | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Mytomicin C | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05250648 ↗ |
| Known as | MMC | “usually changing Oxaliplatin for Mitomycin-C (MMC).” NCT05250648 ↗ |